# Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

> **NCT00622284** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1560 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo identical to BI 1356 5mg
- **DRUG:** Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg
- **DRUG:** BI 1356
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT00622284
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 1560 (ACTUAL)
- **Last updated:** 2014-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622284, "Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00622284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*